Showing results (1761-1770 of 5,261) with videos related to

Sort By:
Pageof 527
Oncology|February 28, 2009
Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancersMaria S Pino, Michele Milella, Alain Gelibter, et al.
Oncology|January 6, 2009
Erlotinib for metastatic non-small-cell lung cancer: first-, second- or third-line setting - does it matter ? A single-institution experienceSikander Ailawadhi, Lyudmyla Derby, Raj Natarajan, et al.
Oncology|June 27, 2009
Phase II study of biweekly docetaxel and S-1 combination therapy for advanced or recurrent gastric cancerYoshihiro Kakeji, Eiji Oki, Akinori Egashira, et al.
Oncology|July 3, 2009
Evaluating quality in clinical cancer research: the M.D. Anderson Cancer Center experienceJames D Cox, Sergio A Giralt, Mary L Veazie, et al.
Oncology|July 25, 2009
Good response to paclitaxel predicts high rates of pathologic complete response for breast cancer patients treated preoperatively with paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamideSeung Jin Kim, Tetsuya Taguchi, Kenzo Shimazu, et al.
Oncology|September 10, 2009
Costs associated with capecitabine or 5-fluorouracil monotherapy after surgical resection in patients with colorectal cancerEdward Chu, Nianwen Shi, Wenhui Wei, et al.
Oncology|January 1, 1977
Inhibition of growth of Morris hepatomas 7777 and 7800 by corn oilJ R Gilbertson, R A Gelman, P Ove, et al.
Oncology|April 15, 2010
Optimal use of targeted agents for advanced gastrointestinal stromal tumoursPeter Reichardt
Oncology|April 2, 2010
Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applicationsJihong Zhang, Malcolm F G Stevens, Charles A Laughton, et al.
Oncology|September 14, 2016
Fever within 2 Weeks of Sorafenib Therapy Predicts Favorable Treatment Efficacy in Patients with Advanced Hepatocellular CarcinomaTeiji Kuzuya, Masatoshi Ishigami, Yoji Ishizu, et al.
Pageof 527